Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of NL003 in Subject With Critical Limb Ischemia（Rutherford 5）

NCT04274049 is registered in ClinicalTrials.gov with Beijing Northland Biotech. Co., Ltd. as lead sponsor.

NCT NCT04274049
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04274049 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of NL003 in Subject With Critical Limb Ischemia（Rutherford 5）
Lead sponsor
Beijing Northland Biotech. Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
August 28, 2019
Completion date
December 23, 2023
Enrollment
242 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

arterial occlusive disease, ischemia, peripheral vascular disease, ulcers